EVOTEC WKN: 566480 ISIN: DE0005664809 Kürzel: EVT Forum: Aktien Thema: Hauptdiskussion

passt fürs erste

über 10,20 schließen wäre ein erster Schritt in die richtige Richtung

Hoffe hier geht bald die Post ab, wie bei Novavax

Furchtbare Krankheit, gerade bei dem Typ II werden Kinder nicht älter als zwei. Wäre toll, wenn da Erfolge einkehren würden...

https://investors.centogene.com/news-releases/news-release-details/centogene-and-evotec-discover-promising-new-molecule-treat

 News Release CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease May 14, 2024 PDF Version CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical research Companies amend existing drug discovery partnership for Evotec to lead continued development. Upon Evotec exercising its option, CENTOGENE to receive an option exercise fee and other potential milestone payments and royalties CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 14, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the discovery of a new small molecule together with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO). The new molecule has the potential to treat patients with type 2 and type 3 Gaucher disease, otherwise known as neuronopathic Gaucher disease. The discovery has been the result of the collaborative work under the existing drug discovery partnership which has been in place since 2020. The Companies have now extended this collaboration for another year, granting Evotec an R&D License for the continued development activities. The amended agreement also provides Evotec with an exclusive option until March 31, 2025, to determine whether to enter a license agreement acquiring CENTOGENE’s share of the IP generated throughout the collaboration. In exchange for such a global exclusive license, CENTOGENE would receive an up-front fee, milestone payments, as well as additional royalties. Further financial details were not disclosed. “This partnership is indicative of how we are able to successfully leverage our expansive know-how in rare diseases as well as the depth of the CENTOGENE Biodatabank, which in combination with Evotec’s multi-modality platform has successfully identified drug candidates in Gaucher disease,” said Dr. Peter Bauer, Chief Medical and Genomic Officer at CENTOGENE. “Importantly, together with Evotec, we have established a much deeper understanding of neuronopathic Gaucher disease than before, which we believe could accelerate the development of a new life-saving treatment for these patients worldwide.” Within their collaboration that was initiated in 2018, CENTOGENE and Evotec have been working together to research, discover, and develop a molecule to reduce the lysosomal molecule lyso-Gb1, which is massively increased in patients with neuronopathic Gaucher disease. The collaboration brought together Evotec’s leading induced pluripotent stem cell (iPSC) platform and broad drug discovery and development capabilities with the CENTOGENE Biodatabank, which contains data from over 850,000 patients, including patient-derived iPSC lines and proprietary translational biomarkers. “We are excited that our highly complementary partnership with CENTOGENE has yielded a first potential treatment for Gaucher disease,” said Dr. Cord Dohrmann, Chief Scientific Officer of Evotec SE. “The identified molecule is the result of combining CENTOGENE’s real-world, data-based, global rare disease platform with Evotec’s broad drug discovery and development capabilities. We look forward to exploring further development options for the promising molecule to deliver a much-needed option for an underserved patient population.” The collaboration has achieved significant success in preclinical studies. In vivo pharmacodynamics and pharmacokinetics studies in animal models have demonstrated high brain penetration and metabolic stability of the drug candidate. This new molecule is now positioned to enter the next stage of R&D, which Evotec is currently pursuing.

Läuft übrigens👍💵

Hab ich beide auf Blockade. Da verpasste wirklich mal rein garnichts!

Und schon hat er es gelöscht 🤣 Evoarm steckt fest im Evodarm

👍😂

Das macht Dich dann zur Kreisklasse B, Du Pfeiffe

Will nicht die Trader hier beurteilen aber dieser evodarm und uss21,.barolo sind Kreisliga maximal

Goldig hier bekommen welche einen orga... Wegen 1.1%

Ok Alibaba 💩💩das habe ich allerdings nicht mit helbel 5

Genau heute den Jackpot gezogen viel Erfolg Will euch nur helfen

Interessant zu sehen das Goldman Sachs nun ca. 5% Anteile hält, aber fast alles verleiht (an wen wohl? -> Leerverkäufer). 2016-2021 waren es auch Goldman Sachs und Morgan Stanley die durch hohe Beteiligung und Aktienleihe unter hohem Volumen die Aktie von 3 auf >40 EUR geschoben unter hoher Vola. Da profitiert man vom auf und ab, geht den Kleinanlegern auf die Nerven und zieht dem armen Michel via StopLoss Fishing günstig die Aktien aus der Tasche.